Arcutis Biotherapeutics Inc. Insider Trading

ARQT

Last 12 months

Insiders sold $16.2M and bought nothing on the open market.

78% of the selling was scheduled in advance under 10b5-1 plans. Director Terrie Curran sold 956K on Aug 27, 62% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2025.

Net open-market

−$16.2M

0 buys · 53 sales

Under a 10b5-1 plan

78%

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Jun 2025

Jun 13, 2025

Get an email when ARQT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2 – 4	Masaru Matsuda EVP, Chief Legal Officer	Sold10b5-1 plan 2 parts	41,219	$34.24 average	$1.41M	27%	Form 4
Nov 2	Patrick Burnett EVP, Chief Medical Officer	SoldNo plan	943	$31.86	30K	0.8%	Form 4
Nov 2	Todd Watanabe See Remarks	SoldNo plan	4,377	$31.86	139K	0.5%	Form 4
Oct 15	Howard G. Welgus Director	Sold10b5-1 plan	4,728	$26.93	127K	12%	Form 4
Sep 16	Masaru Matsuda See Remarks	Sold10b5-1 plan	3,674	$25.00	92K	3.2%	Form 4
Sep 15	Howard G. Welgus Director	Sold10b5-1 plan	4,730	$24.18	114K	12%	Form 4
Sep 8	Masaru Matsuda See Remarks	Sold10b5-1 plan	9,989	$25.03	250K	7.9%	Form 4
Aug 27	Terrie Curran Director	SoldNo plan 2 parts	38,200	$25.03 average	956K	62%	Form 4
Aug 20	Terrie Curran Director	SoldNo plan	1,072	$26.04	28K	4.4%	Form 4
Aug 19	Patrick Burnett See Remarks	SoldNo plan	1,697	$27.00	46K	1.4%	Form 4
Aug 17	Howard G. Welgus Director	Sold10b5-1 plan	4,730	$26.18	124K	11%	Form 4
Aug 11 – 12	Patrick Burnett See Remarks	SoldNo plan 2 parts	15,000	$26.32 average	395K	11%	Form 4
Aug 3	Patrick Burnett See Remarks	Sold10b5-1 plan	955	$26.12	25K	0.8%	Form 4
Aug 3	Masaru Matsuda See Remarks	Sold10b5-1 plan	1,230	$26.12	32K	1.0%	Form 4
Aug 3	Todd Watanabe See Remarks	Sold10b5-1 plan	4,375	$26.12	114K	0.5%	Form 4
Jul 15	Howard G. Welgus Director	Sold10b5-1 plan	4,730	$26.91	127K	11%	Form 4
Jun 15 – 17	Howard G. Welgus Director	Sold10b5-1 plan 2 parts	4,731	$24.58 average	116K	11%	Form 4
Jun 15	Sue-Jean Lin Director	Sold10b5-1 plan	4,946	$24.38	121K	15%	Form 4
May 11	Latha Vairavan SVP Chief Financial Officer	Sold10b5-1 plan	435	$21.05	9K	0.5%	Form 4
May 11	Patrick Burnett See Remarks	Sold10b5-1 plan	222	$21.05	5K	0.2%	Form 4
May 4	Latha Vairavan SVP Chief Financial Officer	Sold10b5-1 plan	1,341	$23.61	32K	1.5%	Form 4
May 4	Todd Watanabe See Remarks	Sold10b5-1 plan	3,172	$23.61	75K	0.4%	Form 4
May 4	Masaru Matsuda See Remarks	Sold10b5-1 plan 2 parts	8,256	$23.31 average	192K	6.1%	Form 4
May 4	Patrick Burnett See Remarks	Sold10b5-1 plan	684	$23.61	16K	0.6%	Form 4
May 1	Howard G. Welgus Director	Sold10b5-1 plan	7,144	$22.99	164K	18%	Form 4
Apr 1	Howard G. Welgus Director	Sold10b5-1 plan	10,000	$23.88	239K	20%	Form 4
Mar 2	Keith R Leonard Director	Sold10b5-1 plan	39,272	$25.39	997K	62%	Form 4
Mar 2	Howard G. Welgus Director	Sold10b5-1 plan	10,000	$25.65	257K	17%	Form 4
Mar 2	Larry Todd Edwards See Remarks	Sold10b5-1 plan 2 parts	3,687	$25.18 average	93K	2.1%	Form 4
Mar 2	Todd Watanabe See Remarks	Sold10b5-1 plan 2 parts	37,349	$25.18 average	941K	4.1%	Form 4
Feb 27 – Mar 2	Masaru Matsuda See Remarks	Sold10b5-1 plan 4 parts	12,058	$26.03 average	314K	8.1%	Form 4
Mar 2	Latha Vairavan SVP Chief Financial Officer	Sold10b5-1 plan 2 parts	2,853	$25.18 average	72K	3.1%	Form 4
Mar 2	Patrick Burnett See Remarks	Sold10b5-1 plan 2 parts	6,287	$25.18 average	158K	4.9%	Form 4
Feb 2 – 4	Patrick Burnett See Remarks	Sold10b5-1 plan 2 parts	13,469	$25.73 average	346K	14%	Form 4
Feb 2	Masaru Matsuda See Remarks	Sold10b5-1 plan 4 parts	40,638	$25.28 average	$1.03M	27%	Form 4
Feb 2	Todd Watanabe See Remarks	Sold10b5-1 plan	19,833	$25.50	506K	2.1%	Form 4
Feb 2	Latha Vairavan SVP Chief Financial Officer	Sold10b5-1 plan	1,320	$25.50	34K	2.0%	Form 4
Feb 2	Howard G. Welgus Director	Sold10b5-1 plan	10,000	$25.05	251K	14%	Form 4
Feb 2	Larry Todd Edwards See Remarks	Sold10b5-1 plan	2,052	$25.50	52K	1.4%	Form 4
Jan 5	Patrick Burnett See Remarks	Sold10b5-1 plan	2,490	$28.98	72K	2.6%	Form 4

Nov 2 – 410b5-1 plan
Masaru Matsuda
EVP, Chief Legal Officer · sold 41,219 at avg $34.24
$1.41M
27% of stake
Nov 2No plan
Patrick Burnett
EVP, Chief Medical Officer · sold 943 at $31.86
30K
0.8% of stake
Nov 2No plan
Todd Watanabe
See Remarks · sold 4,377 at $31.86
139K
0.5% of stake
Oct 1510b5-1 plan
Howard G. Welgus
Director · sold 4,728 at $26.93
127K
12% of stake
Sep 1610b5-1 plan
Masaru Matsuda
See Remarks · sold 3,674 at $25.00
92K
3.2% of stake
Sep 1510b5-1 plan
Howard G. Welgus
Director · sold 4,730 at $24.18
114K
12% of stake
Sep 810b5-1 plan
Masaru Matsuda
See Remarks · sold 9,989 at $25.03
250K
7.9% of stake
Aug 27No plan
Terrie Curran
Director · sold 38,200 at avg $25.03
956K
62% of stake
Aug 20No plan
Terrie Curran
Director · sold 1,072 at $26.04
28K
4.4% of stake
Aug 19No plan
Patrick Burnett
See Remarks · sold 1,697 at $27.00
46K
1.4% of stake
Aug 1710b5-1 plan
Howard G. Welgus
Director · sold 4,730 at $26.18
124K
11% of stake
Aug 11 – 12No plan
Patrick Burnett
See Remarks · sold 15,000 at avg $26.32
395K
11% of stake
Aug 310b5-1 plan
Patrick Burnett
See Remarks · sold 955 at $26.12
25K
0.8% of stake
Aug 310b5-1 plan
Masaru Matsuda
See Remarks · sold 1,230 at $26.12
32K
1.0% of stake
Aug 310b5-1 plan
Todd Watanabe
See Remarks · sold 4,375 at $26.12
114K
0.5% of stake
Jul 1510b5-1 plan
Howard G. Welgus
Director · sold 4,730 at $26.91
127K
11% of stake
Jun 15 – 1710b5-1 plan
Howard G. Welgus
Director · sold 4,731 at avg $24.58
116K
11% of stake
Jun 1510b5-1 plan
Sue-Jean Lin
Director · sold 4,946 at $24.38
121K
15% of stake
May 1110b5-1 plan
Latha Vairavan
SVP Chief Financial Officer · sold 435 at $21.05
9K
0.5% of stake
May 1110b5-1 plan
Patrick Burnett
See Remarks · sold 222 at $21.05
5K
0.2% of stake
May 410b5-1 plan
Latha Vairavan
SVP Chief Financial Officer · sold 1,341 at $23.61
32K
1.5% of stake
May 410b5-1 plan
Todd Watanabe
See Remarks · sold 3,172 at $23.61
75K
0.4% of stake
May 410b5-1 plan
Masaru Matsuda
See Remarks · sold 8,256 at avg $23.31
192K
6.1% of stake
May 410b5-1 plan
Patrick Burnett
See Remarks · sold 684 at $23.61
16K
0.6% of stake
May 110b5-1 plan
Howard G. Welgus
Director · sold 7,144 at $22.99
164K
18% of stake
Apr 110b5-1 plan
Howard G. Welgus
Director · sold 10,000 at $23.88
239K
20% of stake
Mar 210b5-1 plan
Keith R Leonard
Director · sold 39,272 at $25.39
997K
62% of stake
Mar 210b5-1 plan
Howard G. Welgus
Director · sold 10,000 at $25.65
257K
17% of stake
Mar 210b5-1 plan
Larry Todd Edwards
See Remarks · sold 3,687 at avg $25.18
93K
2.1% of stake
Mar 210b5-1 plan
Todd Watanabe
See Remarks · sold 37,349 at avg $25.18
941K
4.1% of stake
Feb 27 – Mar 210b5-1 plan
Masaru Matsuda
See Remarks · sold 12,058 at avg $26.03
314K
8.1% of stake
Mar 210b5-1 plan
Latha Vairavan
SVP Chief Financial Officer · sold 2,853 at avg $25.18
72K
3.1% of stake
Mar 210b5-1 plan
Patrick Burnett
See Remarks · sold 6,287 at avg $25.18
158K
4.9% of stake
Feb 2 – 410b5-1 plan
Patrick Burnett
See Remarks · sold 13,469 at avg $25.73
346K
14% of stake
Feb 210b5-1 plan
Masaru Matsuda
See Remarks · sold 40,638 at avg $25.28
$1.03M
27% of stake
Feb 210b5-1 plan
Todd Watanabe
See Remarks · sold 19,833 at $25.50
506K
2.1% of stake
Feb 210b5-1 plan
Latha Vairavan
SVP Chief Financial Officer · sold 1,320 at $25.50
34K
2.0% of stake
Feb 210b5-1 plan
Howard G. Welgus
Director · sold 10,000 at $25.05
251K
14% of stake
Feb 210b5-1 plan
Larry Todd Edwards
See Remarks · sold 2,052 at $25.50
52K
1.4% of stake
Jan 510b5-1 plan
Patrick Burnett
See Remarks · sold 2,490 at $28.98
72K
2.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ARQT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ARQT

CompareIntrinsic value

ZLABZai Lab Ltd

$22.80+3.83%40

SVASernova Biotherapeutics Inc

No recent price0

INVAInnoviva Inc.

$21.26+1.58%56

NATRNature's Sunshine Products Inc.

$12.84+6.38%70

ESPREsperion Therapeutics Inc.

No recent price50

ORGOOrganogenesis Holdings Inc.

$0.87+4.19%50

ARDXArdelyx Inc.

$3.27+7.92%40

CRMDCorMedix Inc.

$5.66+1.80%84

Held by ETFs

ARQT is in 60 US ETFs. The largest of them, with ARQT's weight in each:

Spot a number that looks wrong? Check it in ARQT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ARQT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.